Medical Oncologist Specializing in Solid Tumors in Guatemala

Systemic treatment of breast cancer based on molecular subtype. Chemotherapy, anti-HER2 therapy, endocrine therapies, and immunotherapy in coordination with surgery and radiotherapy. Management of early, locally advanced, and metastatic disease.

Diagnosis and treatment of non-small cell and small cell lung cancer with complete molecular testing. Detection of EGFR, ALK, ROS1, BRAF, MET mutations and PD-L1 expression to select targeted therapies and immunotherapy.

Treatment of colorectal cancer at all stages with MSI/MMR testing and RAS/BRAF mutation analysis. Chemotherapy, anti-VEGF, anti-EGFR antibodies, and immunotherapy for MSI-high tumors. Management in coordination with surgery and radiotherapy.

Management of prostate cancer at all stages — high-risk localized, hormone-sensitive metastatic, and castration-resistant. Next-generation endocrine therapies, chemotherapy, PARP inhibitors for BRCA mutations, and coordination with urology and radiotherapy.

Diagnosis and treatment of gastric and gastroesophageal junction adenocarcinoma with HER2, PD-L1, and MSI testing. Perioperative chemotherapy, anti-HER2 therapy with trastuzumab, and immunotherapy with pembrolizumab. Specific training in digestive tumors — Universidad Autónoma de Madrid.

Treatment of squamous cell carcinomas of the head and neck in coordination with surgery and radiotherapy. Chemotherapy with cisplatin as a radiosensitizer, cetuximab, and immunotherapy with pembrolizumab or nivolumab for recurrent or metastatic disease.

Diagnosis and treatment of advanced and metastatic melanoma with BRAF mutation testing. Targeted therapy with dabrafenib and trametinib for BRAF-mutated tumors. First-line anti-PD1 and anti-CTLA4 immunotherapy. Management of Merkel cell carcinoma and other advanced skin tumors.

Kidney, bladder, pancreatic, liver, endometrial, and ovarian cancer, neuroendocrine tumors, sarcomas, advanced thyroid, and cervical cancer. Complete molecular diagnosis and up-to-date protocol based on ASCO and ESMO guidelines — regardless of tumor type.

Independent technical review of the oncologic diagnosis, staging, and proposed treatment plan. Recommended before starting treatment, when progressing on current therapy, or when the patient wants to confirm they are receiving the best available treatment for their cancer type and stage.